TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 yrs of age; recipient of ECD/DCD/ECD\&DCD with risk index 3-8 for DGF based on specific criteria~* recipient who are ABO compatible with donor allograft~* pretransplant with meningococcal vaccination~* understand and sign a written consent prior to any study specific procedure.~Risk index (minimum 3- maximum 8):~DGF scale: Donor Age (\<40yr = 0, 41-49yr = 1, 50-54yr = 2, 55-59yr = 3, \>60yr=6), Cold Ischemia Time (0-12= 0, 13-18=1, 19-24=2, 24-30=3, 31-36=4, \>37=6; Recipient Race (nonblack = 0, black =1); Donor death due to Cerebrovascular Accident (CVA) (donor age \<50yrs = 0, donor age \>50yrs = 3).~Exclusion Criteria:~* patients with known prothrombotic disorder (e.g. factor V leiden)~* history of thrombosis or hypercoagulable state excluding access clotting~* history of administration of C1INH containing products or recombinant C1INH within 15 days prior to study entry~* patients with known contraindication to treatment with C1INH~* patients with abnormal coagulation function (INR \>2, partial thromboplastin time (PTT) \> 50, platelets \<80,000)~* who are not on anti-coagulation~* patients with known active presence of malignancies~* Polymerase chain reaction (PCR) positive for hep B/hep C/or HIV~* preemptive kidney transplantation recipient~* recipients of multi-organ transplants (kidney and any other organ)~* recipients of kidney allograft from DD who: cold ischemia time (CIT) \<18h, terminal serum creatinine \</= 1mg/dl, recipient of kidney allograft that was on pump preservation for any period prior to transplantation, recipient of kidney allograft from a living donor, female subject who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- C1-Inhibitor (Berinert) (Human) (C1INH) (Type: EXPERIMENTAL): 35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
- Normal Saline (Type: PLACEBO_COMPARATOR): 35 patients will receive placebo in addition to standard of care immunosuppressive therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn.~* History of episodes of heartburn for 6 months or longer prior to screening.~* History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary.~Exclusion Criteria:~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study·~* Use of antacids (except for study supplied Gelusil®).~* Use of drugs with significant anticholinergic effects.~* Need for continuous anticoagulant (blood thinner) therapy.~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus.~* History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter).~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.~* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the screening endoscopy.~* Erosive Esophagitis seen on endoscopy during study screening.~* Co-existing diseases affecting the esophagus.~* Abnormal laboratory values that suggest significant clinical disease.~* Known acquired immunodeficiency syndrome (AIDS)~* Females pregnant or lactating.~* History of Alcohol abuse.~* History of Cancer within 3 years prior to screening.~* Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors~* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Preterm Pre-labor Rupture of Membranes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age is between 28 wks and 37wks~2. Singleton living pregnancy.~3. Confirmed Premature Pre-labor rupture of membranes (PPROM).~Exclusion Criteria:~1. previable rupture of membranes (\<23+6wks)~2. Multiple gestations~3. Macrolide allergy~4. patient receiving combination macrolide therapy~5. lethal fetal anomalies~6. contraindications to expectant management of PPROM at time of diagnosis e.g. concurrent preterm labor, placental abruption, chorioamnionitis or non-reassuring fetal testing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin 1 day group (Type: OTHER): Patients will receive Azithromycin 1000mg once orally
- Azithromycin 5 days group (Type: OTHER): Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is able to provide written informed consent before beginning any study related procedures~* Patient has a documented clinical diagnosis of major depressive disorder~* Patient is able to understand and comply with the requirements of the study, as judged by a study investigator~Exclusion Criteria:~* Patients with a history of non-compliance as judged by the study investigator~* Patients with a known lack of response to previous treatment with quetiapine~* Patients who have participated in a clinical trial within 4 weeks of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven, untreated, primary desmoid tumor (aggressive fibromatosis) for which surgery and/or radiation therapy is not thought to be feasible (prior attempted surgical resection allowed if gross residual disease remains) No other fibroblastic lesions or other fibromatoses allowed Recurrent desmoid tumor not previously treated with vinca alkaloids or methotrexate and no chemotherapy since recurrence Measurable disease by MRI~PATIENT CHARACTERISTICS: Age: Under 19 at time of diagnosis Performance status: Not specified Life expectancy: Not specified Hematopoietic: Hemoglobin normal for age WBC normal for age Platelet count normal for age Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) for age SGOT less than 1.5 times ULN for age Renal: Creatinine less than 1.5 times ULN for age~PRIOR CONCURRENT THERAPY: See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy Treatment (Type: EXPERIMENTAL): Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ARDS with a PaO2 / FiO2 \< 150 with a PEEP \> 5 since less than 48 hrs~* informed consent~Exclusion Criteria:~* NMBA allergy~* Continuous administration of NMBA for ARDS prior inclusion~* Age \< 18 yrs~* SAPS II \> 70~* Persistent air leak

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy male or female, between, and including, 6 and 12 weeks of age.~* Born after a gestation period between 36 and 42 weeks~* Vaccination with hepatitis B at birth and at 6 to 12 weeks (concomitantly with the first study vaccine), accepted although not mandatory~Exclusion criteria:~* Planned administration/ administration of a vaccine not foreseen by the study protocol since birth, with the exception of Bacille Calmette Guerin (BCG) and hepatitis B vaccines.~* History of H. influenzae type b and /or meningococcal serogroup C disease.~* Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus, pertussis, polio or Hib disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection~* A family history of congenital or hereditary immunodeficiency~* History of any neurologic disorders or seizures~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. edss\<5~2. \>=1 attack in last year~Exclusion Criteria:~1. \>2 attacks in study~2. drug complication

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMART Trial: Intrapersonal and Interpersonal Stigma Reduction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Identify as African American, Black, or mixed race~* Identify as someone with a substance use disorder who is not currently in treatment OR a support person of someone enrolled~* Access to a telephone for follow-up assessment~* Reside in the Memphis, TN area~Exclusion Criteria:~* Unable to understand consent procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intrapersonal Stigma Reduction (Type: EXPERIMENTAL): The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
- Interpersonal Stigma Reduction (Type: EXPERIMENTAL): The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-of-1 Trials In Children With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* treating physician determines that pharmacologic therapy is indicated for treatment of hypertension~* ambulatory hypertension has been confirmed (off meds) within 12 months of enrollment~Exclusion Criteria:~* age \< 10 years~* resistant hypertension (requiring ≥ 3 drug therapy)~* absolute contraindication or allergy to any of the tested drugs.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- NICHE method (Type: EXPERIMENTAL): In the NICHE method, antihypertensive therapy will be chosen using an n-of-1 trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
- Usual Care (Type: ACTIVE_COMPARATOR): No protocol will be introduced to standardize BP management in the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Four to fifteen AKs on the face~* histologically confirmed presence of abnormal architecture and satellite atypical keratinocytes in the epidermis, in clinically normal tissue samples of photodamaged skin adjacent to AKs~* at least one previously treated nonmelanoma skin cancer (NMSC) on the head and/or neck area within the past five years~Exclusion Criteria:~* Pregnancy~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area~* skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* Subject is immunosuppressed~* unsuccessful outcome from previous ALA-PDT therapy~* currently enrolled in an investigational drug or device study~* has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment~* known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)~* has an active herpes simplex infection OR a history of 2 or more outbreaks within the past 12 months, on the face~* use of the following topical preparations on the extremity to be treated:~  * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days~ * Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks~ * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-fluorouracil (5-FU), diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK within 8 weeks~* use of systemic retinoid therapy within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALA X3 (Type: EXPERIMENTAL): Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
- VEH (Type: PLACEBO_COMPARATOR): Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
- ALA X2 (Type: EXPERIMENTAL): Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic renal anemia;~* continuous iv maintenance epoetin alfa therapy, with the same dosing interval during the previous month to and during SVP;~* regular hemodialysis for greater than or equal to (\>=) 3 months~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months~* poorly controlled hypertension requiring interruption of epoetin alfa treatment in previous 6 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A (Type: EXPERIMENTAL): Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete